Floatz logo

Ifx-Hu2.0

Cutaneous Melanoma

TuHURA Biosciences, Inc.vaccineEarly Phase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

142 Active assets in the Cutaneous Melanoma cohort.

Asset / SponsorPhaseRating
Alpha-Interferon
MIPO Clinic
Phase 3BBB
Tyrosinase Peptide
University of Southern California
Phase 3BBB
TIL
City of Hope Medical Center
Phase 2BBB
Cis-Diamminedichloroplatinum Ii
MIPO Clinic
Phase 3BBB
Dacarbazine
Linnaeus Therapeutics, Inc.
Phase 3BBB

View all 50 →

Same molecule, other indications

Ifx-Hu2.0 is also rated in:

cutaneous neuroendocrine carcinomaActive
B
Indicative · Phase 2/3
60 / 100
View asset →
skin carcinomaDormant
CC
Indicative · Phase 1
47 / 100
View asset →
skin squamous cell carcinomaDormant
CC
Indicative · Phase 1
44 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →